Shearman & Sterling advised the underwriters in connection with the follow-on public offering by Inari Medical, Inc. of two million shares of common stock at a public offering price of $81 per share, resulting in gross proceeds to Inari of approximately $162 million.
BofA Securities and Morgan Stanley acted as joint book-running managers for the offering and Wells Fargo Securities, Canaccord Genuity and BTIG acted as co-managers.
Inari is a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases. The company's current product offerings consist of two minimally-invasive, novel catheter-based mechanical thrombectomy devices, which are purpose-built for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism – deep vein thrombosis and pulmonary embolism. Inari also has a number of products under development and remains focused on creating purpose-built systems for the treatment of a specific disease state.
The Shearman & Sterling team below was supported by associates Jai Lakhani (New York–Capital Markets), and Jordan Briggs (New York–Financial Institutions Advisory & Financial Regulatory).